At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
Cabotamig (ARB202)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
In Brief
A Phase 1 clinical trial evaluating Cabotamig (ARB202) for Gastrointestinal Cancer and 8 related conditions. Completed, enrolled 33 participants across 3 sites in 2 countries.
Detailed Summary
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2. To find out how study drug is broken down in the body 3. To know the effects of the study drug on the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma, Pancreatic Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastroesophageal Junction, Gastrointestinal Neuroendocrine Tumors
CountriesAustralia, Hong Kong
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartMay 2022
First PostedJun 2022
Primary CompletionJul 2025
TodayJul 2026
First PostedJun 9, 2022
Enrollment StartMay 30, 2022
Primary CompletionJul 23, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.1 years ago
Interventions
Cabotamig (ARB202)drug
Cabotamig (ARB202), Atezolizumab